GLENBIO LTD

1. Credit Opinion: APPROVE

Glenbio Ltd presents a strong credit profile suitable for commercial credit facilities. The company demonstrates a consistent and robust history of profitability and retained earnings, with net assets growing from £174k in 2017 to £1.57M as of January 2025. The business operates a debt-light capital structure with minimal long-term liabilities (£36k). While cash reserves have seen a significant year-on-year decline, this is primarily attributed to a substantial capital investment in freehold property rather than operational distress. The company's solid equity base, strong working capital position, and consistent growth trajectory provide ample capacity to service new debt obligations.

2. Financial Strength

The balance sheet is exceptionally healthy and demonstrates disciplined financial stewardship: * Strong Equity Base: Shareholders' funds stand at £1.57M, entirely funded by retained profits (P&L reserve of £1.57M against a mere £100 share capital), highlighting highly efficient historical cash generation. * Asset Growth: Total assets grew from £2.26M to £2.51M. Most notably, tangible assets surged from £278k to £760k following £496k of additions to freehold property. This transition from leased/held assets to owned property is a positive indicator of business permanence and collateral strength. * Low Leverage: Long-term creditors are negligible at £36k. The company is not highly leveraged, meaning any new credit facilities would easily be serviced from operational cash flows without threatening the capital structure. * Contingent Liabilities: There is a minor director's loan owed by Mr. McIntosh (£4,740), which is immaterial and does not present a conflict of interest or risk of cash extraction.

3. Cash Flow Assessment

While the balance sheet is strong, the cash flow and working capital dynamics require contextual analysis: * Liquidity Position: Cash at bank fell sharply from £826k to £390k. However, this £435k cash depletion is explained by the £496k capital expenditure on freehold property and an increase in trade debtors. This is a strategic deployment of cash, not a sign of margin erosion. * Working Capital: Net current assets remain robust at £845k. The current ratio stands at approximately 1.9x (£1.75M / £0.9M), indicating ample short-term liquidity to cover trade creditors and operational expenses. * Debtor Book: Trade debtors increased by 40% (from £416k to £583k). This could indicate normal business growth, but it may also signal slower collections or extended payment terms to customers. Given that stocks also remain high (£730k), working capital is currently absorbing significant cash. * Creditor Stance: Trade creditors increased modestly to £516k, but "other creditors" jumped from £205k to £331k. The nature of these other creditors should be verified (e.g., whether they are deferred income/prepayments or actual operational liabilities).

4. Monitoring Points

If a facility is granted, the following metrics should be monitored annually: * Trade Debtor Days: The expansion in trade debtors needs to be reconciled against revenue growth. If debtor days are stretching, it indicates potential collection risk or a need to fund customer terms. * Cash Conversion Post-Capex: With the major property acquisition complete, cash generation should normalize in subsequent periods. We should expect to see cash reserves rebuild in the 2026 financial year. * Stock Levels: Stocks remain high at £730k. Given the nature of chemical manufacturing, monitor for potential obsolescence or write-downs that could erode the current asset base. * Composition of "Other Creditors": Clarification should be sought on the £331k in other current creditors to ensure no hidden short-term debt or operational liabilities are accumulating.